Bayer Proposes $7.25 Billion Roundup Settlement Over Cancer Claims: What You Need to Know

Bayer just proposed a $7.25 billion settlement to resolve tens of thousands of lawsuits alleging its popular weedkiller Roundup caused non-Hodgkin lymphoma, a serious type of cancer that affects the lymphatic system.

The proposed class action settlement, announced on February 17, was filed in St. Louis Circuit Court in Missouri. If approved, it would cover both people who have already filed lawsuits and those who may be diagnosed with non-Hodgkin lymphoma in the future after being exposed to Roundup.

Roundup contains glyphosate, a widely used herbicide. While the EPA has said glyphosate is not likely to be carcinogenic when used as directed, multiple studies and court cases have linked it to an increased risk of non-Hodgkin lymphoma. Roughly 200,000 Roundup-related claims have been filed against Bayer since the company acquired Roundup maker Monsanto in 2018.

Bayer has already paid over $11 billion in prior Roundup settlements and jury verdicts — including a $2.1 billion award by a Georgia jury in 2025.

How the settlement would work

The $7.25 billion would be paid into a fund over a 21-year period. Compensation would be tiered based on the type of non-Hodgkin lymphoma diagnosis, age at diagnosis, and the nature and extent of a person's exposure to Roundup.

According to the proposed settlement terms, average payouts could range from around $10,000 to $165,000 depending on the case. An occupational user diagnosed with an aggressive form of NHL before age 60 could see an average payout of $165,000, with individual awards varying from 80% to 120% of the average.

The settlement also includes a "Quick-Pay" program for certain cases that would offer smaller, faster payouts.

Who qualifies

To be eligible, a person must have been exposed to Roundup before February 17, 2026 — meaning they personally purchased or applied the product — and have a medical diagnosis of non-Hodgkin lymphoma. The settlement also covers people who are diagnosed with NHL within 16 years after the court gives final approval.

This is not a typical consumer class action where anyone who bought a product can file a claim for a few dollars. This is a mass tort settlement specifically for people who developed cancer allegedly linked to Roundup exposure.

What happens next

The settlement still needs court approval. Bayer's previous attempt at a class action settlement was rejected by a federal judge in 2022 for having terms deemed unfair to cancer patients.

On top of this settlement, the U.S. Supreme Court is set to hear oral arguments on April 27 in a separate case about whether federal pesticide labeling laws should block state-level failure-to-warn lawsuits against Bayer. A ruling in Bayer's favor could significantly reduce the company's future legal exposure.

Bayer has not admitted any wrongdoing as part of this proposed settlement.

The bottom line

If you or someone you know used Roundup and has been diagnosed with non-Hodgkin lymphoma, this proposed settlement could mean compensation is available. If the court approves the deal, payments could begin later this year.

Download ClassyAction to stay updated on this settlement and get notified when payouts begin.